Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 323

1.

Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.

Balaian E, Weidner H, Wobus M, Baschant U, Jacobi A, Mies A, Bornhäuser M, Guck J, Hofbauer LC, Rauner M, Platzbecker U.

Ann Hematol. 2019 Jul 16. doi: 10.1007/s00277-019-03756-1. [Epub ahead of print]

PMID:
31312928
2.

A Novel Strategy for Repairing Multiple Myeloma Bone Lesions: Lessons From Murine Models.

Calvi LM, Hofbauer LC.

J Bone Miner Res. 2019 May;34(5):781-782. doi: 10.1002/jbmr.3723. Epub 2019 May 9. No abstract available.

PMID:
31071234
3.

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients.

Göbel A, Kuhlmann JD, Link T, Wimberger P, Link-Rachner C, Thiele S, Dell'Endice S, Furesi G, Breining D, Rauner M, Hofbauer LC, Rachner TD.

J Bone Oncol. 2019 Apr 4;16:100237. doi: 10.1016/j.jbo.2019.100237. eCollection 2019 Jun.

4.

Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signaling.

Rauner M, Baschant U, Roetto A, Pellegrino RM, Rother S, Salbach-Hirsch J, Weidner H, Hintze V, Campbell G, Petzold A, Lemaitre R, Henry I, Bellido T, Theurl I, Altamura S, Colucci S, Muckenthaler MU, Schett G, Komla Ebri D, Bassett JHD, Williams GR, Platzbecker U, Hofbauer LC.

Nat Metab. 2019 Jan;1(1):111-124. doi: 10.1038/s42255-018-0005-8. Epub 2019 Jan 7.

5.

Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation.

Kresinsky A, Schnöder TM, Jacobsen ID, Rauner M, Hofbauer LC, Ast V, König R, Hoffmann B, Svensson CM, Figge MT, Hilger I, Heidel FH, Böhmer FD, Müller JP.

Oncogene. 2019 Jun;38(24):4773-4787. doi: 10.1038/s41388-019-0757-y. Epub 2019 Feb 28.

PMID:
30820040
6.

Osteogenic Dkk1 Mediates Glucocorticoid-Induced but Not Arthritis-Induced Bone Loss.

Colditz J, Thiele S, Baschant U, Garbe AI, Niehrs C, Hofbauer LC, Rauner M.

J Bone Miner Res. 2019 Feb 19. doi: 10.1002/jbmr.3702. [Epub ahead of print]

PMID:
30779862
7.

Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties.

Picke AK, Campbell G, Napoli N, Hofbauer LC, Rauner M.

Endocr Connect. 2019 Mar 1;8(3):R55-R70. doi: 10.1530/EC-18-0456. Review.

8.

Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.

Göbel A, Breining D, Rauner M, Hofbauer LC, Rachner TD.

Cell Death Dis. 2019 Jan 28;10(2):91. doi: 10.1038/s41419-019-1322-x.

9.

The Role of Dickkopf-1 in Thyroid Hormone-Induced Changes of Bone Remodeling in Male Mice.

Tsourdi E, Colditz J, Lademann F, Rijntjes E, Köhrle J, Niehrs C, Hofbauer LC, Rauner M.

Endocrinology. 2019 Mar 1;160(3):664-674. doi: 10.1210/en.2018-00998.

PMID:
30689850
10.

Trabectedin Reduces Skeletal Prostate Cancer Tumor Size in Association with Effects on M2 Macrophages and Efferocytosis.

Jones JD, Sinder BP, Paige D, Soki FN, Koh AJ, Thiele S, Shiozawa Y, Hofbauer LC, Daignault S, Roca H, McCauley LK.

Neoplasia. 2019 Feb;21(2):172-184. doi: 10.1016/j.neo.2018.11.003. Epub 2018 Dec 31.

11.

Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer.

Rachner TD, Kasimir-Bauer S, Göbel A, Erdmann K, Hoffmann O, Browne A, Wimberger P, Rauner M, Hofbauer LC, Kimmig R, Bittner AK.

Clin Cancer Res. 2019 Feb 15;25(4):1369-1378. doi: 10.1158/1078-0432.CCR-18-2482. Epub 2018 Nov 13.

PMID:
30425091
12.

Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin.

Rachner TD, Hofbauer LC, Göbel A, Tsourdi E.

J Mol Endocrinol. 2019 Feb 1;62(2):R145-R154. doi: 10.1530/JME-18-0173. Review.

PMID:
30389901
13.

Thy-1 Deficiency Augments Bone Loss in Obesity by Affecting Bone Formation and Resorption.

Picke AK, Campbell GM, Schmidt FN, Busse B, Rauner M, Simon JC, Anderegg U, Hofbauer LC, Saalbach A.

Front Cell Dev Biol. 2018 Oct 2;6:127. doi: 10.3389/fcell.2018.00127. eCollection 2018.

14.

Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment.

Tsourdi E, Makras P, Rachner TD, Polyzos S, Rauner M, Mandanas S, Hofbauer LC, Anastasilakis AD.

Bone. 2019 Mar;120:44-49. doi: 10.1016/j.bone.2018.10.001. Epub 2018 Oct 4.

PMID:
30292818
15.

β-Blockers and bone health.

Hofbauer LC, Henneicke H.

J Clin Invest. 2018 Nov 1;128(11):4745-4747. doi: 10.1172/JCI122992. Epub 2018 Oct 2.

16.

Thy-1 (CD90) promotes bone formation and protects against obesity.

Picke AK, Campbell GM, Blüher M, Krügel U, Schmidt FN, Tsourdi E, Winzer M, Rauner M, Vukicevic V, Busse B, Salbach-Hirsch J, Tuckermann JP, Simon JC, Anderegg U, Hofbauer LC, Saalbach A.

Sci Transl Med. 2018 Aug 8;10(453). pii: eaao6806. doi: 10.1126/scitranslmed.aao6806.

PMID:
30089635
17.

Differential effects of high-fat diet and exercise training on bone and energy metabolism.

Picke AK, Sylow L, Møller LLV, Kjøbsted R, Schmidt FN, Steejn MW, Salbach-Hirsch J, Hofbauer C, Blüher M, Saalbach A, Busse B, Rauner M, Hofbauer LC.

Bone. 2018 Nov;116:120-134. doi: 10.1016/j.bone.2018.07.015. Epub 2018 Jul 20.

PMID:
30036679
18.

Apalutamide and Metastasis-free Survival in Prostate Cancer.

Rachner TD, Tsourdi E, Hofbauer LC.

N Engl J Med. 2018 Jun 28;378(26):2541-2. doi: 10.1056/NEJMc1806189. No abstract available.

PMID:
29952180
19.

Role of WNT5A receptors FZD5 and RYK in prostate cancer cells.

Thiele S, Zimmer A, Göbel A, Rachner TD, Rother S, Fuessel S, Froehner M, Wirth MP, Muders MH, Baretton GB, Jakob F, Rauner M, Hofbauer LC.

Oncotarget. 2018 Jun 5;9(43):27293-27304. doi: 10.18632/oncotarget.25551. eCollection 2018 Jun 5.

20.

Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo.

Hildebrandt S, Baschant U, Thiele S, Tuckermann J, Hofbauer LC, Rauner M.

Sci Rep. 2018 Jun 7;8(1):8711. doi: 10.1038/s41598-018-26300-z.

21.

Selective inhibition of receptor activator of NF-κB ligand (RANKL) in hematopoietic cells improves outcome after experimental myocardial infarction.

Slavic S, Andrukhova O, Ford K, Handschuh S, Latic N, Reichart U, Sasgary S, Bergow C, Hofbauer LC, Kostenuik PJ, Erben RG.

J Mol Med (Berl). 2018 Jun;96(6):559-573. doi: 10.1007/s00109-018-1641-x. Epub 2018 May 8.

22.

Postnatal Skeletal Deletion of Dickkopf-1 Increases Bone Formation and Bone Volume in Male and Female Mice, Despite Increased Sclerostin Expression.

Colditz J, Thiele S, Baschant U, Niehrs C, Bonewald LF, Hofbauer LC, Rauner M.

J Bone Miner Res. 2018 Sep;33(9):1698-1707. doi: 10.1002/jbmr.3463. Epub 2018 Jun 12.

PMID:
29734465
23.

Associations of myeloid hematological diseases of the elderly with osteoporosis: A longitudinal analysis of routine health care data.

Datzmann T, Trautmann F, Tesch F, Mies A, Hofbauer LC, Platzbecker U, Schmitt J.

Leuk Res. 2018 Jun;69:81-86. doi: 10.1016/j.leukres.2018.04.010. Epub 2018 Apr 21.

PMID:
29705535
24.

Denosumab: a new treatment option for glucocorticoid-induced osteoporosis.

Tsourdi E, Hofbauer LC.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):428-429. doi: 10.1016/S2213-8587(18)30097-4. Epub 2018 Apr 6. No abstract available.

PMID:
29631783
25.

Bone health during endocrine therapy for cancer.

Rachner TD, Coleman R, Hadji P, Hofbauer LC.

Lancet Diabetes Endocrinol. 2018 Nov;6(11):901-910. doi: 10.1016/S2213-8587(18)30047-0. Epub 2018 Mar 20. Review.

PMID:
29572126
26.

Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.

Tsourdi E, Rachner TD, Hofbauer LC.

N Engl J Med. 2018 Jan 11;378(2):195. doi: 10.1056/NEJMc1714810. No abstract available.

PMID:
29322753
27.

Immunoadsorption Followed by Rituximab as a Definitive Treatment for Insulin Autoimmune Syndrome (Hirata Syndrome): A Case Report.

Kroemer TM, Erler A, Tsourdi E, Gruber M, Tselmin S, Julius U, Aringer M, Hofbauer LC, Rachner TD.

Diabetes Care. 2018 Mar;41(3):e23-e24. doi: 10.2337/dc17-1974. Epub 2017 Dec 27. No abstract available.

PMID:
29282202
28.

Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway.

Balaian E, Wobus M, Weidner H, Baschant U, Stiehler M, Ehninger G, Bornhäuser M, Hofbauer LC, Rauner M, Platzbecker U.

Haematologica. 2018 Jan;103(1):61-68. doi: 10.3324/haematol.2017.172726. Epub 2017 Oct 27.

29.

Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism.

Tsourdi E, Lademann F, Ominsky MS, Rijntjes E, Köhrle J, Misof BM, Roschger P, Klaushofer K, Hofbauer LC, Rauner M.

Endocrinology. 2017 Nov 1;158(11):3765-3777. doi: 10.1210/en.2017-00247.

PMID:
28973221
30.

Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer.

Browne AJ, Kubasch ML, Göbel A, Hadji P, Chen D, Rauner M, Stölzel F, Hofbauer LC, Rachner TD.

Breast Cancer Res. 2017 Aug 9;19(1):92. doi: 10.1186/s13058-017-0885-7.

31.

Immune Suppressive and Bone Inhibitory Effects of Prednisolone in Growing and Regenerating Zebrafish Tissues.

Geurtzen K, Vernet A, Freidin A, Rauner M, Hofbauer LC, Schneider JE, Brand M, Knopf F.

J Bone Miner Res. 2017 Dec;32(12):2476-2488. doi: 10.1002/jbmr.3231. Epub 2017 Sep 13.

32.

Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells.

Streicher C, Heyny A, Andrukhova O, Haigl B, Slavic S, Schüler C, Kollmann K, Kantner I, Sexl V, Kleiter M, Hofbauer LC, Kostenuik PJ, Erben RG.

Sci Rep. 2017 Jul 25;7(1):6460. doi: 10.1038/s41598-017-06614-0.

33.

Osteoporosis treatment: recent developments and ongoing challenges.

Khosla S, Hofbauer LC.

Lancet Diabetes Endocrinol. 2017 Nov;5(11):898-907. doi: 10.1016/S2213-8587(17)30188-2. Epub 2017 Jul 7. Review.

34.

Prediction of Fractures and Major Cardiovascular Events in Men Using Serum Osteoprotegerin Levels: The Prospective STRAMBO Study.

Szulc P, Chapurlat R, Hofbauer LC.

J Bone Miner Res. 2017 Nov;32(11):2288-2296. doi: 10.1002/jbmr.3213. Epub 2017 Aug 7.

35.

Site-Specific Variations in Bone Mineral Density under Systemic Conditions Inducing Osteoporosis in Minipigs.

Schulz MC, Kowald J, Estenfelder S, Jung R, Kuhlisch E, Eckelt U, Mai R, Hofbauer LC, Stroszczynski C, Stadlinger B.

Front Physiol. 2017 Jun 20;8:426. doi: 10.3389/fphys.2017.00426. eCollection 2017.

36.

Bone Mass Is Compromised by the Chemotherapeutic Trabectedin in Association With Effects on Osteoblasts and Macrophage Efferocytosis.

Sinder BP, Zweifler L, Koh AJ, Michalski MN, Hofbauer LC, Aguirre JI, Roca H, McCauley LK.

J Bone Miner Res. 2017 Oct;32(10):2116-2127. doi: 10.1002/jbmr.3196. Epub 2017 Aug 31.

37.

Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.

Göbel A, Kuhlmann JD, Link T, Wimberger P, Browne AJ, Rauner M, Hofbauer LC, Rachner TD.

Breast Cancer Res Treat. 2017 Aug;164(3):737-743. doi: 10.1007/s10549-017-4296-3. Epub 2017 May 19.

PMID:
28526959
38.

[New Osteoanabolic Therapies for Osteoporosis].

Tsourdi E, Lademann F, Hofbauer LC.

Dtsch Med Wochenschr. 2017 Apr;142(7):475-478. doi: 10.1055/s-0042-122721. Epub 2017 Apr 7. German. No abstract available.

PMID:
28388741
39.

Myelodysplastic syndromes and bone loss in mice and men.

Weidner H, Rauner M, Trautmann F, Schmitt J, Balaian E, Mies A, Helas S, Baschant U, Khandanpour C, Bornhäuser M, Hofbauer LC, Platzbecker U.

Leukemia. 2017 Apr;31(4):1003-1007. doi: 10.1038/leu.2017.7. Epub 2017 Jan 11. No abstract available.

PMID:
28074069
40.

Bone Formation and the Wnt Signaling Pathway.

Rauner M, Rachner TD, Hofbauer LC.

N Engl J Med. 2016 Nov 10;375(19):1902. doi: 10.1056/NEJMc1609768. No abstract available.

PMID:
27959644
41.

Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A.

N Engl J Med. 2016 Oct 20;375(16):1532-1543. Epub 2016 Sep 18.

42.

Sclerostin Blockade-A Dual Mode of Action After All?

Baschant U, Henneicke H, Hofbauer LC, Rauner M.

J Bone Miner Res. 2016 Oct;31(10):1787-1790. doi: 10.1002/jbmr.2988. Epub 2016 Sep 14. No abstract available.

43.

Increased EPO Levels Are Associated With Bone Loss in Mice Lacking PHD2 in EPO-Producing Cells.

Rauner M, Franke K, Murray M, Singh RP, Hiram-Bab S, Platzbecker U, Gassmann M, Socolovsky M, Neumann D, Gabet Y, Chavakis T, Hofbauer LC, Wielockx B.

J Bone Miner Res. 2016 Oct;31(10):1877-1887. doi: 10.1002/jbmr.2857. Epub 2016 May 13.

44.

Postmenopausal osteoporosis.

Eastell R, O'Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT, Cummings SR.

Nat Rev Dis Primers. 2016 Sep 29;2:16069. doi: 10.1038/nrdp.2016.69. Review.

PMID:
27681935
45.

Role of milk fat globule-epidermal growth factor 8 in osteoimmunology.

Sinningen K, Thiele S, Hofbauer LC, Rauner M.

Bonekey Rep. 2016 Jul 20;5:820. doi: 10.1038/bonekey.2016.52. eCollection 2016. Review.

46.

Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors.

Baschant U, Rauner M, Balaian E, Weidner H, Roetto A, Platzbecker U, Hofbauer LC.

Haematologica. 2016 Dec;101(12):1499-1507. Epub 2016 Aug 18.

47.

Effects of insulin therapy on porosity, non-enzymatic glycation and mechanical competence in the bone of rats with type 2 diabetes mellitus.

Campbell GM, Tiwari S, Picke AK, Hofbauer C, Rauner M, Morlock MM, Hofbauer LC, Glüer CC.

Bone. 2016 Oct;91:186-93. doi: 10.1016/j.bone.2016.08.003. Epub 2016 Aug 4.

PMID:
27497735
48.

Microdialysis Sampling from Wound Fluids Enables Quantitative Assessment of Cytokines, Proteins, and Metabolites Reveals Bone Defect-Specific Molecular Profiles.

Förster Y, Schmidt JR, Wissenbach DK, Pfeiffer SE, Baumann S, Hofbauer LC, von Bergen M, Kalkhof S, Rammelt S.

PLoS One. 2016 Jul 21;11(7):e0159580. doi: 10.1371/journal.pone.0159580. eCollection 2016.

49.

WNT5A and Its Receptors in the Bone-Cancer Dialogue.

Thiele S, Rachner TD, Rauner M, Hofbauer LC.

J Bone Miner Res. 2016 Aug;31(8):1488-96. doi: 10.1002/jbmr.2899. Review.

50.

Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes.

Sellmeyer DE, Civitelli R, Hofbauer LC, Khosla S, Lecka-Czernik B, Schwartz AV.

Diabetes. 2016 Jul;65(7):1757-66. doi: 10.2337/db16-0063. Review.

Supplemental Content

Loading ...
Support Center